PDCD1 and neoplasm: Combining CDA inhibitors with both gemcitabine and anti-PD-1 therapy may have synergic effects, potentiating the cytotoxic impact of gemcitabine on cancer cells and tumor immunogenicity51,52 and enabling the immune system to act against the tumor in response to anti-PD-1.